tiprankstipranks
Advertisement
Advertisement

HK:2696 Stock Latest News

Henlius Delivers Strong Interim Growth and Expands EU Cancer Drug Footprint
Company AnnouncementsHenlius Delivers Strong Interim Growth and Expands EU Cancer Drug Footprint
23h ago
2696
Shanghai Henlius Biotech Added to Hang Seng Composite Index, Boosting Market Profile
PremiumCompany Announcements
Shanghai Henlius Biotech Added to Hang Seng Composite Index, Boosting Market Profile
23h ago
2696
Henlius Strikes Global Biosimilar Alliance with Sandoz
PremiumCompany Announcements
Henlius Strikes Global Biosimilar Alliance with Sandoz
5d ago
2696
Shanghai Henlius Biotech Sets August Board Meeting to Approve Interim Results
PremiumCompany Announcements
Shanghai Henlius Biotech Sets August Board Meeting to Approve Interim Results
19d ago
2696
Henlius Wins NMPA Nod to Start New HLX43 Combination Trials in China
PremiumCompany Announcements
Henlius Wins NMPA Nod to Start New HLX43 Combination Trials in China
22d ago
2696
Henlius Starts First-in-Human Trial of Novel Trispecific Prostate Cancer Antibody
PremiumCompany AnnouncementsHenlius Starts First-in-Human Trial of Novel Trispecific Prostate Cancer Antibody
23d ago
2696
Shanghai Henlius Biotech Grants New Share Options and RSUs to Strengthen Incentives
Premium
Company Announcements
Shanghai Henlius Biotech Grants New Share Options and RSUs to Strengthen Incentives
1M ago
2696
Henlius Doses First Patient in Global Trial of Nivolumab Biosimilar HLX18
Premium
Company Announcements
Henlius Doses First Patient in Global Trial of Nivolumab Biosimilar HLX18
1M ago
2696
Henlius Wins NMPA Nod for HLX37 and HLX43 Combination Trial in Advanced Solid Tumours
PremiumCompany Announcements
Henlius Wins NMPA Nod for HLX37 and HLX43 Combination Trial in Advanced Solid Tumours
1M ago
2696
Henlius Doses First Patient in Phase 1 Trial for Cetuximab Biosimilar HLX05-N
PremiumCompany Announcements
Henlius Doses First Patient in Phase 1 Trial for Cetuximab Biosimilar HLX05-N
2M ago
2696
Henlius Starts First-in-Human Trial of Novel Dual-Target Cancer ADC HLX48
PremiumCompany Announcements
Henlius Starts First-in-Human Trial of Novel Dual-Target Cancer ADC HLX48
2M ago
2696
Henlius Doses First U.S. Patient in Global Trial of Ipilimumab Biosimilar HLX13
PremiumCompany Announcements
Henlius Doses First U.S. Patient in Global Trial of Ipilimumab Biosimilar HLX13
2M ago
2696
Henlius wins EU nod for new lung cancer use of serplulimab
PremiumCompany AnnouncementsHenlius wins EU nod for new lung cancer use of serplulimab
2M ago
2696
Henlius Wins GMP Green Light for HANBEIYOU Production in Mainland China
Premium
Company Announcements
Henlius Wins GMP Green Light for HANBEIYOU Production in Mainland China
2M ago
2696
Henlius Wins NMPA Nod for First-in-Class Trispecific Prostate Cancer Therapy Trial
Premium
Company Announcements
Henlius Wins NMPA Nod for First-in-Class Trispecific Prostate Cancer Therapy Trial
2M ago
2696
Henlius Wins Australian Nod for Phase 2 NSCLC Trial of HLX43 Combo
PremiumCompany Announcements
Henlius Wins Australian Nod for Phase 2 NSCLC Trial of HLX43 Combo
2M ago
2696
Henlius Phase 3 Eye Drug HLX04-O Hits Key Goals in Global wAMD Trial
PremiumCompany Announcements
Henlius Phase 3 Eye Drug HLX04-O Hits Key Goals in Global wAMD Trial
2M ago
2696
Henlius Wins China Approval for New Gastric Cancer Use of HANSIZHUANG
PremiumCompany Announcements
Henlius Wins China Approval for New Gastric Cancer Use of HANSIZHUANG
2M ago
2696
Henlius Starts Global Phase 1 Trial of Pembrolizumab Biosimilar HLX17 in U.S. and China
PremiumCompany Announcements
Henlius Starts Global Phase 1 Trial of Pembrolizumab Biosimilar HLX17 in U.S. and China
3M ago
2696
Henlius Wins China Approval for HANBEIYOU Breast Cancer Biosimilar
PremiumCompany AnnouncementsHenlius Wins China Approval for HANBEIYOU Breast Cancer Biosimilar
3M ago
2696
Henlius Starts Global Phase 2/3 Trial of ADC HLX43 in Advanced Lung Cancer
Premium
Company Announcements
Henlius Starts Global Phase 2/3 Trial of ADC HLX43 in Advanced Lung Cancer
3M ago
2696
Henlius Starts First-Patient Dosing in Phase 1 Study of Daratumumab Biosimilar HLX15-SC for Newly Diagnosed Multiple Myeloma
Premium
Company Announcements
Henlius Starts First-Patient Dosing in Phase 1 Study of Daratumumab Biosimilar HLX15-SC for Newly Diagnosed Multiple Myeloma
3M ago
2696

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >